Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Thursday, 1 November 2007

Press Release of the Week: Drug Delivery!

Posted on 09:00 by Unknown
Most of the releases we receive are from dedicated health care PR pros. If the topics aren't right up our alley, then they tend to be at least tangentially related to what we cover. But yesterday we got a doozy. Put it this way: we never thought we'd be considering the question "Which Air Cannon is right for me?" At least not during our day jobs.

Although this latest bit of press-release inspired amusement is right out of left field, but it did inspire us in a we-thought-everyone-was-done-making-fun-of-Exubera-but-maybe-not sort of way. What you see up there on the right is an "Air Cannon." It's hard to imagine the PR guy who is pitching a biopharma-medical device magazine on a story about these babies really thinks it'd be of much use to, say, Pfizer or Medtronic (or for that matter thinks much at all), but we gave it a shot:
  • next-generation Exubera inhaler
  • tired of waiting for your prescription to be filled at the pharmacy? Just give the pharmacist your coordinates and wait for your statins to land on your front lawn
  • spice up panel discussions by shooting "My vice president of business development went to Pharmaceutical Strategic Alliances and all i got was this lousy T-shirt" shirts into an unsuspecting audience
So any of you PR folks out there who can occasionally find us unresponsive ... take note. When Air Cannons, Inc. Provides Creative Ways to Whip Crowds into a Frenzy shows up in the old in-box, we're all over it.
Email ThisBlogThis!Share to XShare to Facebook
Posted in Exubera, PR, Press Release of the Week | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • While You Were Settling
    Well, it was an interesting weekend: the writers' strike may have been settled, Obama swept (and won a Grammy), and there was an unusual...
  • EPO Relabeling: Its Not the Black Box, Its What FDA Says About the Black Box
    Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...
  • The Wacky World of Generics: Fosamax Edition
    Today, Merck bids a fond farewell to its Fosamax franchise, as the first generic versions enter the market. Three generic firms are enteri...
  • Higher Tax, Fewer Deals?
    The IN VIVO Blog has been somewhat mum on the carried interest debate. Frankly, this topic is being covered to death elsewhere (The link g...
  • CardioNet's Not So Big Surprise
    Riddle us this. When is news not news at all? When it’s involving CardioNet Inc.’s Friday filing for an IPO . See, this filing was essential...
  • While You Were Staying Put
    It's always sunny in ... London? Lets kick off the weekend wrap-up by highlighting a trio of stories from The Times about incoming Glax...
  • While You Were Almost Upsetting
    We've been told by certain football (soccer) fans that there are not enough allusions to the beautiful game in our weekend roundups. So ...
  • FDA’s Search for a Drug Chief Not Going Well: An Internal Candidate Emerges
    We know all of you have been passing the time following the Presidential Primaries when the race you’re really interested in is who the next...
  • While You Were Redesigning Your Blog
    Does our blog look big in this? You may have noticed a few changes round these parts, and we hope you like them. No, not that the pace of o...
  • The Downsizing Opportunity: Pipeline on the Cheap?
    The IN VIVO Blog was in Michigan last week, attending a profiting-from-downsizing symposium. Would Pfizer—we wondered at the Michigan Growth...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ▼  November (42)
      • Prasugrel: Lilly Tries to Stop the Bleeding (Part 1)
      • Deals of the Week: For Sale By Owner
      • Has Forest Found a Successful NDA Path?
      • Sanofi Aventis Walks the Talk
      • Sirtris Strikes Again
      • Emergent Emerges
      • DTC User Fees Clear First Hurdle; New Era for Adve...
      • Frazier Joins $600m Club
      • The Values Debate: How Much is Your Drug Worth?
      • While You Were Giving Thanks
      • Quite A Set of Lung (Companies)
      • Uncertainty Surrounds FDAAA Implementation
      • Deals of the Week: The Alice's Restaurant Edition ...
      • What's Next for Celgene?
      • Who Needs VCs?
      • Pharmion’s Euro Bet Pays Off
      • DTC User Fees: Will This Program Fly?
      • Delivery Delays
      • While You Were Acquiring
      • Venture Rounds: You Stay Classy, San Diego
      • Deals of the Week: The Break Up to Make Up Edition
      • Why Genzyme's Unlikely to be the Next Target
      • Avandia’s Black Box: FDA Office of New Drugs Wins
      • Where's the Love?
      • Why Doesn't Pharma Hire from Biotech?
      • Dicerna Announces Series A, Nastech Announces Spin...
      • Ventana Plays Ball
      • Disappearing Act
      • Co-Promotes are Out. Extra Royalties are In
      • While You Were ...
      • EPO Relabeling: Its Not the Black Box, Its What FD...
      • Deals of the Week--the Rerun Edition
      • Biovitrum Sheds PC Assets
      • Shire Steps Up Pressure on Genzyme
      • The Disaggregation Road
      • What Does the FDA Drug Safety Law Mean for Drug De...
      • Horse Sense
      • Momenta: Oh, Sugar!
      • The Expanding Pharmaceutical Desert
      • While You Were at AHA
      • Deals of the Week: "King of Pain" Edition
      • Press Release of the Week: Drug Delivery!
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ►  May (43)
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile